RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Inovio Pharmaceuticals - Stock

Inovio Pharmaceuticals Stocks 2024

Inovio Pharmaceuticals Stocks

22.17 M

Ticker

INO

ISIN

US45773H2013

WKN

A115GK

In 2024, Inovio Pharmaceuticals had 22.17 M outstanding stocks, a 0% change from the 22.17 M stocks in the previous year.

The Inovio Pharmaceuticals Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e22.17
2028e22.17
2027e22.17
2026e22.17
2025e22.17
2024e22.17
202322.17
202219.88
202117.4
202012.93
20198.23
20187.71
20176.82
20166.1
20155.68
20144.93
20133.84
20122.84
20112.63
20102.15
20091.56
20080.92
20070.86
20060.66
20050.4
20040.37

Inovio Pharmaceuticals shares outstanding

The number of shares was Inovio Pharmaceuticals in 2023 — This indicates how many shares 22.174 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Inovio Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Inovio Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Inovio Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Inovio Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Inovio Pharmaceuticals Aktienanalyse

What does Inovio Pharmaceuticals do?

Inovio Pharmaceuticals Inc. is a US biotechnology and pharmaceutical company specializing in the development of DNA vaccines and immunotherapies. It was founded in 1979 by Dr. Joseph Kim and is headquartered in Plymouth Meeting, Pennsylvania. Inovio began working on DNA-based vaccines in the late 1990s and developed the Electroporation technology, which facilitates the introduction of DNA molecules into cells. The company has expanded its capabilities over the years and is able to generate immune responses against a variety of viruses and bacteria. They have also made advancements in using their technology to combat cancer. Inovio's business model is based on licensing technologies and collaborating with partners such as pharmaceutical companies, government agencies, and academic institutions. They also offer services for the development and production of DNA-based vaccines for academic and industrial customers. Inovio is divided into different divisions, including DNA vaccines for infectious diseases and oncology, platform technology, and cancer immunotherapy. They offer a wide range of DNA vaccines for infectious diseases such as HPV, HIV, hepatitis B and C, as well as Lassa fever and Ebola. Inovio has also made significant progress in the development of DNA-based immunotherapies for cancer, using Electroporation technology to train and activate T-cells against cancer cells. In terms of products, Inovio has various products in different stages of clinical development, but they have not yet received FDA approval for any of their products. However, they have successfully conducted clinical trials for vaccines such as HPV, which has shown 90% efficacy against the virus. In conclusion, Inovio is a specialized company in the development of DNA-based vaccines and immunotherapy for cancer. Their Electroporation technology has led to significant breakthroughs, and they continue to pursue partnerships and further development. With their focus on research and development and advancing their technologies, it seems that Inovio is on a path of continued success. Inovio Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Inovio Pharmaceuticals's Shares Outstanding

Inovio Pharmaceuticals's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Inovio Pharmaceuticals’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Inovio Pharmaceuticals’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Inovio Pharmaceuticals’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Inovio Pharmaceuticals Stock

How many stocks are there of Inovio Pharmaceuticals?

The current number of stocks of Inovio Pharmaceuticals is 22.17 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Inovio Pharmaceuticals are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Inovio Pharmaceuticals evolved in recent years?

The number of shares of Inovio Pharmaceuticals has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Inovio Pharmaceuticals as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Inovio Pharmaceuticals?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Inovio Pharmaceuticals pay?

Over the past 12 months, Inovio Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Inovio Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Inovio Pharmaceuticals?

The current dividend yield of Inovio Pharmaceuticals is .

When does Inovio Pharmaceuticals pay dividends?

Inovio Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Inovio Pharmaceuticals?

Inovio Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Inovio Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Inovio Pharmaceuticals located?

Inovio Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Inovio Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Inovio Pharmaceuticals from 7/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/3/2024.

When did Inovio Pharmaceuticals pay the last dividend?

The last dividend was paid out on 7/3/2024.

What was the dividend of Inovio Pharmaceuticals in the year 2023?

In the year 2023, Inovio Pharmaceuticals distributed 0 USD as dividends.

In which currency does Inovio Pharmaceuticals pay out the dividend?

The dividends of Inovio Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Inovio Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Inovio Pharmaceuticals

Our stock analysis for Inovio Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Inovio Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.